Skip to main content
SpringerLink
Log in

Is Vascular Mortality Increased in Hypopituitarism?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Hitherto four relevant cohort studies have been published on the life expectancy of patients with hypopituitarism, two from the UK and two from Sweden. In all four studies patients with acromegaly or Cushing's disease were excluded, and patients with GH replacement were not included. A crude meta-analysis, not considering differences in validity of the study designs, gives an overall Relative Risk (RR) of 1.47, with a relatively small 95% confidence interval of 1.27–1.70. The aim of this critical review was to assess whether lacking validity in the design of one or several of these studies indicates that the true RR might be higher or lower than indicated by meta-analyses. A high frequency of cranial irradiation in one of the Swedish cohorts may explain part of the very high observed RR for cerebrovascular mortality, but there remained a 40% risk increase for cardiac diseases that cannot be explained by irradiation. Some other validity problems, especially seen in the UK studies, will result in under-estimation of the true RR, but for others the direction of bias is uncertain due to lacking information in the original publications. According to our view, it is more probable that the observed overall 50% risk increase for vascular mortality is an under-estimation than an over-estimation of the true RR. This analysis is of a qualitative nature, and it is not possible to quantify to what extent the lacking validity may have affected the RR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bates AS, Bukkivant B, Sheppard MC, Stewart PM. Life expectancy following surgery for pituitary tumors. Clin Endocrinol 1999;50:315–319.

    Google Scholar 

  2. Bates AS, Hoff WV, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169–1172.

    Google Scholar 

  3. Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–288.

    Google Scholar 

  4. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypoptituitarism. Clin Endocrinol 1997;46:75–81.

    Google Scholar 

  5. Aase A. Regionalizing mortality data: ischemic heart disease in Norway. Soc Sci Med 1989;29:907–911.

    Google Scholar 

  6. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of cardiovascular disease mortality in Europe. Eur Heart J 1997;18:1231–1248.

    Google Scholar 

  7. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596–601.

    Google Scholar 

  8. Lindholm J, Rasmussen P, Korsgaard O. Endocrine function in patients with pituitary adenoma before and after hypophysectomy. Acta Endocrinol (Copenh) 1976;82:52–61.

    Google Scholar 

  9. Salmi J. Endocrine dysfunction before and after operation in patients with chromofobe pituitary adenoma. Thesis, University of Helsinki 1979.

  10. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumors in adults. Q J Med 1988;262:145–160.

    Google Scholar 

  11. Webb SM, Rigla M, Wägner A, Oliver B, Bartumeus F. Recovery of pituitary function after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 1999;84:3696–3700.

    Google Scholar 

  12. Murros KE, Toole JF. The effect of radiation on carotid arteries. Arch Neurol 1989;46:449–455.

    Google Scholar 

  13. Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson B-Å. Cardiovascular riskfactors in adult patients with growth hormone deficiency. Acta Endocrinol 1993;129:195–200.

    Google Scholar 

  14. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides, AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992;340:1188–1192.

    Google Scholar 

  15. Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson BÅ, Strasburger CJ, and the Adult Growth Hormone Deficiency Study Group. Adult growth hormone deficient patients demonstrate heterogenity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82–88.

    Google Scholar 

  16. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effect of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797–1803.

    Google Scholar 

  17. Cuneo RC, Salomon F, Watts GF, Hesp R, Sönksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993;42:1519–1523.

    Google Scholar 

  18. Johannsson G, Oscarsson J, Rosén T, Wiklund O, Olsson G, Wilhelmsen L, Bengtsson BÅ. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo (E) phenitypes. Arterioscler Thromb Vasc Biol 1995;15:2142–2150.

    Google Scholar 

  19. Bengtsson B-Å, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström L, Isaksson O. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309–317.

    Google Scholar 

  20. Snel YEM, Brummer R-JM, Doerga ME, Zelissen PMJ, Bakker CJG, Hendriks MJ, Koppeschaar HPF. Adipose tissue assessed by magnetic resonance imaging in growth-hormone deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995;61:1290–1294.

    Google Scholar 

  21. Johansson J-O, Landin K, Johansson G, Tengborn L, Bengtsson B-Å. Long-term effects with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone deficcient adults. Thromb Haemost 1996;76:422–428.

    Google Scholar 

  22. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russel-Jones D. The effect of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999;84:2596–2602

    Google Scholar 

  23. Pfeiffer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton R. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999;84:453–457

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine, Division of Endocrinology (EME, BB) and Occupational and Environmental Medicine (LH), University Hospital, SE-221 85, Lund, Sweden

    Eva Marie Therese Erfurth, Birgitta BüAlow & Lars Erik Hagmar

Authors
  1. Eva Marie Therese Erfurth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgitta BüAlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Erik Hagmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erfurth, E.M.T., BüAlow, B. & Hagmar, L.E. Is Vascular Mortality Increased in Hypopituitarism?. Pituitary 3, 77–81 (2000). https://doi.org/10.1023/A:1009901707125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009901707125

Search

Navigation